All In Biotech

Drug Trial Radar · NCT06034743

A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 796 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

796

Actual

Start

Nov 22, 2023

Primary completion

May 21, 2025

Study completion Oct 10, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Sep 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 720 participants aged ≥ 18 years with hypertension, despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uncontrolled hypertension); or ≥ 3 antihypertensive agents at baseline, one of which is a diuretic (treatment-resistant hypertension).

Conditions

  • Uncontrolled Hypertension
  • Resistant Hypertension

Interventions

  • BaxdrostatDrug

    Baxdrostat tablet administered orally, once daily (QD). Unit dose strengths: * 1 mg per tablet for 1 mg baxdrostat Arm; * 2 mg per tablet for 2 mg baxdrostat Arm.

  • PlaceboDrug

    Placebo tablet matching baxdrostat, administered orally, once daily (QD).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Seated Systolic Blood Pressure for 2 mg BaxdrostatTime frame: At Week 12
  2. Change From Baseline in Seated Systolic Blood Pressure for 1 mg BaxdrostatTime frame: At Week 12

Locations

263 sites in 29 countries. Site status is shown where the registry gives one.

  • Research Site

    Saraland, Alabama

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Sun City West, Arizona

  • Research Site

    Surprise, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Fresno, California

  • Research Site

    Lincoln, California

  • Research Site

    Orange, California

  • Research Site

    Rancho Cucamonga, California

  • Research Site

    Stanford, California

  • Research Site

    New Haven, Connecticut

  • Research Site

    Clearwater, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Port Orange, Florida

  • Research Site

    Decatur, Georgia

  • Research Site

    East Point, Georgia

  • Research Site

    Springfield, Illinois

  • Research Site

    Munster, Indiana

  • Research Site

    Lexington, Kentucky

  • Research Site

    Detroit, Michigan

  • Research Site

    Rochester, Minnesota

  • Research Site

    Olive Branch, Mississippi

  • Research Site

    Kansas City, Missouri

  • Research Site

    Kansas City, Missouri

  • Research Site

    Kansas City, Missouri

  • Research Site

    Rosedale, New York

  • Research Site

    The Bronx, New York

  • Research Site

    Chapel Hill, North Carolina

  • Research Site

    New Bern, North Carolina

  • Research Site

    Toledo, Ohio

  • Research Site

    Grants Pass, Oregon

  • Research Site

    Bethlehem, Pennsylvania

  • Research Site

    Langhorne, Pennsylvania

  • Research Site

    East Providence, Rhode Island

  • Research Site

    Memphis, Tennessee

  • Research Site

    Brownsville, Texas

  • Research Site

    Corpus Christi, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Sugar Land, Texas

  • Research Site

    Manassas, Virginia

Showing 40 of 263 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.